We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+18.21%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.42B
AUM Growth
+$59.6M
Cap. Flow
-$61.6M
Cap. Flow %
-4.35%
Top 10 Hldgs %
62.23%
Holding
38
New
7
Increased
10
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$51.6M
2
RLAY icon
Relay Therapeutics
RLAY
+$39.7M
3
CDTX
Cidara Therapeutics
CDTX
+$28.2M
4
KYMR icon
Kymera Therapeutics
KYMR
+$25.8M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$22.8M

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$62.3M
2
MRUS
Merus
MRUS
+$44.6M
3
SLNO
Soleno Therapeutics
SLNO
+$40.4M
4
VERA icon
Vera Therapeutics
VERA
+$39.6M
5
COGT icon
Cogent Biosciences
COGT
+$36.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.44%
2 Financials 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
26
Apogee Therapeutics
APGE
$10.2B
$12.6M 0.89%
290,000
– –
IKT icon
27
Inhibikase Therapeutics
IKT
$366M
$10.5M 0.74%
5,397,488
+53,056
+1% +$104K
PCSC
28
DELISTED
Perceptive Capital Solutions
PCSC
$7.96M 0.56%
750,000
– –
TNGX icon
29
Tango Therapeutics
TNGX
$4.34B
$7.68M 0.54%
+1,500,000
New +$3.71M
CBIO
30
Crescent Biopharma
CBIO
$602M
$7.32M 0.52%
+453,686
New +$9.6M
NGNE icon
31
Neurogene
NGNE
$696M
$6.4M 0.45%
427,866
-497,134
-54% -$7.8M
VTGN icon
32
VistaGen Therapeutics
VTGN
$9.29M
$3.15M 0.22%
1,575,000
– –
AVTX icon
33
Avalo Therapeutics
AVTX
$976M
$2.41M 0.17%
483,000
– –
CELC icon
34
Celcuity
CELC
$4.03B
– –
-695,650
Closed -$7.03M
CRDF icon
35
Cardiff Oncology
CRDF
$64.3M
– –
-5,384,616
Closed -$16.9M
ORIC icon
36
Oric Pharmaceuticals
ORIC
$1.25B
– –
-2,000,000
Closed -$11.2M
PCVX icon
37
Vaxcyte
PCVX
$7.89B
– –
-1,650,000
Closed -$62.3M
SLDB icon
38
Solid Biosciences
SLDB
$771M
– –
-5,825,000
Closed -$21.6M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Commodore Capital held 38 positions worth $1.42B, up 4.4% from $1.36B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Commodore Capital withdrew a net $61.6M in Q2 2025, closing 5 positions and reducing 8 holdings. Its most notable exit was Vaxcyte, an estimated $62.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Commodore Capital opened a new position in Protagonist Therapeutics worth $59.4M.

  • Commodore Capital's largest Q2 2025 buy was Protagonist Therapeutics: 1,075,000 shares worth $59.4M.
  • Commodore Capital added most to Xenon Pharmaceuticals in Q2 2025, an estimated $22.8M increase.
  • Commodore Capital's biggest Q2 2025 reduction was Merus, cutting an estimated $44.6M.
  • Commodore Capital fully exited Vaxcyte in Q2 2025, selling an estimated $62.3M.
  • Commodore Capital's ten largest holdings make up 62% of its $1.42B portfolio in Q2 2025.
  • Commodore Capital opened 7 new positions and closed 5 in Q2 2025.
  • Commodore Capital's portfolio value rose 4.4% quarter-over-quarter to $1.42B.

Based on Commodore Capital's 13F filing for Q2 2025, filed 14 Aug 2025.